INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect

Bibliography

• Jemal A, Siegel R, Ward E, Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96
   PubMed Web of Science ®Google Scholar
• Johnson DH. Management of small cell lung cancer: current state of the art. Chest 1999;116:525S-30S
   PubMed Web of Science ®Google Scholar
• Johnson BE. Management of small cell lung cancer. Clin Chest Med 2002;23:225-39
   PubMed Web of Science ®Google Scholar
• Simon GR, Wagner H. Small cell lung cancer. Chest 2003;123:259S-71S
   PubMed Web of Science ®Google Scholar
• von Pawel J, Schiller JH, Shepherd FA, Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658-67
   PubMed Web of Science ®Google Scholar
• Ardizzoni A. Topotecan in the treatment of recurrent small cell lung cancer: an update. Oncologist 2004;9(Suppl 6):4-13
   PubMedGoogle Scholar
• Davies AM, Evans WK, Mackay JA, Treatment of recurrent small cell lung cancer. Hematol Oncol Clin North Am 2004;18:387-416
   PubMed Web of Science ®Google Scholar
• Mattson K, Niiranen A, Ruotsalainen T, Interferon maintenance therapy for small cell lung cancer: improvement in long-term survival. J Interferon Cytokine Res 1997;17:103-5
   PubMed Web of Science ®Google Scholar
• Prior C, Oroszy S, Oberaigner W, Adjunctive interferon-alpha-2c in stage IIIB/IV small-cell lung cancer: a phase III trial. Eur Respir J 1997;10:392-6
   PubMed Web of Science ®Google Scholar
• Zarogoulidis K, Ziogas E, Papagiannis A, Interferon alpha-2a and combined chemotherapy as first line treatment in SCLC patients: a randomized trial. Lung Cancer 1996;15:197-205
   PubMed Web of Science ®Google Scholar
• Clamon G, Herndon J, Perry MC, Interleukin-2 activity in patients with extensive small-cell lung cancer: a Phase II trial of Cancer and Leukemia Group B. J Natl Cancer Inst 1993;85:316-20
   PubMed Web of Science ®Google Scholar
• Kelley MJ, Linnoila RI, Avis IL, Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer. Chest 1997;112:256-61
   PubMed Web of Science ®Google Scholar
• Chikamatsu K, Nakano K, Storkus WJ, Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells. Clin Cancer Res 1999;5:1281-8
   PubMed Web of Science ®Google Scholar
• Liu DP, Song H, Xu Y. A common gain of function of p53 cancer mutants in inducing genetic instability. Oncogene 2009;29:949-56
   Google Scholar
• van Oijen MG, Slootweg PJ. Gain-of-function mutations in the tumor suppressor gene p53. Clin Cancer Res 2000;6:2138-45
   PubMed Web of Science ®Google Scholar
• Vierboom MP, Nijman HW, Offringa R, Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J Exp Med 1997;186:695-704
   PubMed Web of Science ®Google Scholar
• Mayordomo JI, Loftus DJ, Sakamoto H, Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 1996;183:1357-65
   PubMed Web of Science ®Google Scholar
• Zwaveling S, Vierboom MP, Ferreira Mota SC, Antitumor efficacy of wild-type p53-specific CD4+ T-helper cells. Cancer Res 2002;62:6187-93
   PubMed Web of Science ®Google Scholar
• Parajuli P, Pisarev V, Sublet J, Immunization with wild-type p53 gene sequences coadministered with Flt3 ligand induces an antigen-specific type 1 T-cell response. Cancer Res 2001;61:8227-34
   PubMed Web of Science ®Google Scholar
• Eura M, Chikamatsu K, Katsura F, A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck. Clin Cancer Res 2000;6:979-86
   PubMedGoogle Scholar
• Theobald M, Ruppert T, Kuckelkorn U, The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope. J Exp Med 1998;188:1017-28
   PubMed Web of Science ®Google Scholar
• Vierboom MP, Gabrilovich DI, Offringa R, p53: a target for T cell mediated immunotherapy. In: Kast WM, editor, Peptide-based cancer vaccines. Landes Bioscience, Georgetown, TX; 2000: p. 40-55
   Google Scholar
• Brossart P, Goldrath AW, Butz EA, Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J Immunol 1997;158:3270-6
   PubMed Web of Science ®Google Scholar
• Wan Y, Bramson J, Carter R, Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination. Hum Gene Ther 1997;8:1355-63
   PubMed Web of Science ®Google Scholar
• Specht JM, Wang G, Do MT, Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J Exp Med 1997;186:1213-21
   PubMed Web of Science ®Google Scholar
• Thomson SA, Khanna R, Gardner J, Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design. Proc Natl Acad Sci USA 1995;92:5845-9
   PubMed Web of Science ®Google Scholar
• Becker TC, Noel RJ, Coats WS, Use of recombinant adenovirus for metabolic engineering of mammalian cells. Methods Cell Biol 1994;43:161-76
   PubMed Web of Science ®Google Scholar
• Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 1997;89:21-39
   PubMed Web of Science ®Google Scholar
• Brossart P, Goldrath AW, Butz EA, Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J Immunol 1997;158:3270-6
   PubMed Web of Science ®Google Scholar
• Dietz AB, Vuk-Pavlovic S. High efficiency adenovirus-mediated gene transfer to human dendritic cells. Blood 1998;91:392-8
   PubMed Web of Science ®Google Scholar
• Wan Y, Bramson J, Carter R, Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination. Hum Gene Ther 1997;8:1355-63
   PubMed Web of Science ®Google Scholar
• Nikitina EY, Chada S, Muro-Cacho C, An effective immunization and cancer treatment with activated dendritic cells transduced with full-length wild-type p53. Gene Ther 2002;9:345-52
   PubMed Web of Science ®Google Scholar
• Ishida T, Chada S, Stipanov M, Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses. Clin Exp Immunol 1999;117:244-51
   PubMed Web of Science ®Google Scholar
• Nikitina EY, Clark JI, Van Beynen J, Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients. Clin Cancer Res 2001;7:127-35
   PubMed Web of Science ®Google Scholar
• D'Amico D, Carbone D, Mitsudomi T, High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. Oncogene 1992;7:339-46
   PubMed Web of Science ®Google Scholar
• Bodner SM, Minna JD, Jensen SM, Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 1992;7:743-9
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Mirza N, Fricke I, Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 2006;12:878-87
   PubMed Web of Science ®Google Scholar
• Chiappori A, Sereno M, Gabrilovich D, Phase II trial of patients with extensive stage small cell lung cancer immunized with p53-transduced dendritic cells: immune sensitization to chemotherapy. Proc Am Soc Clin Oncol 2007;25: abstract 3012
   Google Scholar
• Pisarev V, Yu B, Salup R, Full-length dominant-negative survivin for cancer immunotherapy. Clin Cancer Res 2003;15:6523-33
   Google Scholar
• Kusmartsev S, Gabrilovich DI. Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol Immunother 2002;51:293-8
   PubMed Web of Science ®Google Scholar
• Gabrilovich D. The mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 2004;4:941-52
   PubMed Web of Science ®Google Scholar
• Mirza N, Fishman M, Fricke I, All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 2006;66:9299-307
   PubMed Web of Science ®Google Scholar
• Bronte V, Apolloni E, Cabrelle A, Identification of a CD11b+/Gr-1+/CD31+ myeloid progenitor capable of activating or suppressing CD8+ T cells. Blood 2000;96:3838-46
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Velders MP, Sotomayor EM, Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol 2001;166:5398-406
   PubMed Web of Science ®Google Scholar
• Kusmartsev S, Cheng F, Yu B, All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res 2003;63:4441-9
   PubMed Web of Science ®Google Scholar
• Almand B, Clark JI, Nikitina E, Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001;166:678-89
   PubMed Web of Science ®Google Scholar
• Smit EF, Fokkema E, Biesma B, A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer 1998;77:347-51
   PubMed Web of Science ®Google Scholar
• Nimmanapalli R, Perkins CL, Orlando M, Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res 2001;61:759-63
   PubMed Web of Science ®Google Scholar
• Hopkins-Donaldson S, Ziegler A, Kurtz S, Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ 2003;10:356-64
   PubMed Web of Science ®Google Scholar
• Ramakrishnan R, Antonia S, Gabrilovich DI. Combined modality immunotherapy and chemotherapy: a new perspective. Cancer Immunol Immunother 2008;57:1523-9
   PubMed Web of Science ®Google Scholar
• Radfar S, Wang Y, Khong HT. Activated CD4+ T cells dramatically enhance chemotherapeutic tumor responses in vitro and in vivo. J Immunol 2009;183:6800-7
   PubMed Web of Science ®Google Scholar
• Wheeler CJ, Das A, Liu G, Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res 2004;10:5316-26
   PubMed Web of Science ®Google Scholar
• Gribben JG, Ryan DP, Boyajian R, Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res 2005;11:4430-6
   PubMed Web of Science ®Google Scholar
• Arlen PM, Gulley JL, Parker C, A randomized Phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 2006;12:1260-9
   PubMed Web of Science ®Google Scholar
• Arlen PM, Madan RA, Hodge JW, Combining vaccines with conventional therapies for cancer. Update Cancer Ther 2007;2:33-9
   PubMedGoogle Scholar
• Schlom J, Arlen PM, Gulley JL. Cancer vaccines: moving beyond current paradigms. Clin Cancer Res 2007;13:3776-82
   PubMed Web of Science ®Google Scholar
• Gulley JL, Madan RA, Arlen PM. Enhancing efficacy of therapeutic vaccinations by combination with other modalities. Vaccine 2007;25(Suppl 2):B89-96
   PubMedGoogle Scholar
• Schlom J, Gulley JL, Arlen PM. Paradigm shifts in cancer vaccine therapy. Exp Biol Med (Maywood) 2008;233:522-34
   PubMed Web of Science ®Google Scholar
• Ozao-Choy J, Ma G, Kao J, The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 2009;69:2514-22
   PubMed Web of Science ®Google Scholar
• Cady SG, Sono M. 1-Methyl-DL-tryptophan, beta-(3-benzofuranyl)-DL-alanine (the oxygen analog of tryptophan), and beta-[3-benzo(b)thienyl]-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase. Arch Biochem Biophys 1991;291:326-33
   PubMed Web of Science ®Google Scholar
• Ribas A, Hanson DC, Noe DA, Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist 2007;12:873-83
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Flaherty KT, Khalil M, Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 2007;25:876-83
   PubMed Web of Science ®Google Scholar